PositiveID CSO and Former DHS
Chief Scientist Calls for "Nunn-Lugar Act 2.0" to
Dismantle Unprecedented
Chemical and Biological
Weapons Stockpile in North Korea
"Two
Minutes to Doomsday" article views North Korea's chemical
and biological weapons as greater threat than
nuclear
Delray Beach, FL --
June
05, 2018 --
InvestorsHub NewsWire -- PositiveID Corporation ("PositiveID" or "Company")
(OTC:PSID)
ExcitePCR subsidiary today
announced publication of an article co-authored by Chief Science Officer
Kimothy Smith, DVM, Ph.D., calling for an update
of
the
previous
critical
effort to
dismantle former Soviet nuclear weapons for the current threat
of modern
chemical and biological weapons of mass
destruction,
particularly in North Korea. The article,
"Two Minutes
to Doomsday Time for Nunn-Lugar 2.0," can be found on the Security
Debrief website.
North Korea Bio
Threat
The Democratic
People's
Republic
of Korea (DPRK) has the third largest stock of
chemical weapons on the planet according to the
article, including nerve, blister, blood, and vomiting agents.
The next
cooperative
threat reduction
program must
be as focused on the chemical and biological threats as much or
more than the nuclear threat, according to article
authors.
Prior to his move
to the private
sector in 2008, Dr. Smith was the Senior Advisor for International
Biodefense for the Department of Homeland Security (DHS), Office of
Health Affairs. In that role
he served as
detailee to the Office of International Health & Biodefense of
the U.S. State Department.
During this period as an
expert specialist, he
coordinated
biodefense and emergency response strategies with international
partners and facilitated dialogue on food safety and
agricultural security. He also served
as Acting Director
of the National Biosurveillance Integration
Center.
Importance of
On-Site Detection
Dr. Smith recently published a
report for the U.S. Department of Defense's Homeland Defense &
Security Information Analysis Center concluding quick deployment of
user-friendly diagnostics is critical to successful containment of
an agroterrorismevent.
PositiveID is
developing the FireflyDX family of products
to
automate
real-time
pathogen detection
at the point of care/point of need
(POC/PON) faster and less expensively than existing
devices.
FireflyDX's
on-site pathogen detection
applications
are expected
to include human clinical, such as
infectious disease
and hospital acquired infections, global food and agricultural
screening, and biological warfare and
biothreat defense.
About PositiveID
Corporation
PositiveID Corporation is a
holding company with a focus on life sciences tools and
diagnostics. PositiveID's ExcitePCR subsidiary develops biological
detection and diagnostics systems, specializing in the development
of microfluidic systems for the automated preparation of and
performance of biological assays. PositiveID's Thermomedics
subsidiary markets the FDA-cleared Caregiver non-contact infrared
thermometer. PositiveID also owns a minority interest in E-N-G
Mobile Systems, a leader in the specialty vehicle market.
For more
information on PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID
on Twitter, Facebook or LinkedIn.
On August 24, 2017, the Company
and its wholly-owned subsidiary PDI (collectively, the "Seller"),
entered into an Asset Purchase Agreement ("APA") with its
majority-owned subsidiary, ExcitePCR (the "Buyer"). Pursuant to the
APA, at closing, the Company will own approximately 91% of
ExcitePCR post-closing of the sale. The Buyer has not yet fulfilled
the conditions to close the transaction which include ExcitePCR
completing a financing of at least $3 million.
Statements about PositiveID's future expectations,
including the likelihood that FireflyDX's onsite pathogen
detection applications are expected to include human clinical, such
as infectious disease and hospital acquired infections, global food
and agricultural screening, and biological warfare and biothreat
defense; constitute "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933,
Section 21E of the Securities Exchange Act of 1934, and as that
term is defined in the Private Litigation Reform Act of 1995. Such
forward-looking statements involve risks and uncertainties and are
subject to change at any time, and PositiveID's actual results
could differ materially from expected results. These risks and
uncertainties include, without limitation, the Company's
ability to complete the testing and development of FireflyDX;
the Company's ability to raise capital; the Company's
ability to close the APA; as well as other risks.
Additional information about these and other factors that could
affect the Company's business is set forth in the Company's various
filings with the Securities and Exchange Commission, including
those set forth in the Company's 10-K filed on April 2, 2018, and
10-Qs filed on May 18, 2018, November 13,
2017, and August 14, 2017, under the caption
"Risk Factors." The Company undertakes no obligation to update or
release any revisions to these forward-looking statements to
reflect events or circumstances after the date of this statement or
to reflect the occurrence of unanticipated events, except as
required by law.
Contact:
PositiveID
Corporation
Allison Tomek
(561) 805-8044
atomek@psidcorp.com